Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison

International Journal of Urology

Volumn 20, Issue 10, 2013, Pages 971-978

  Brusa, Davide ^a,b   Simone, Mariagrazia ^a,b   Gontero, Paolo ^a   Spadi, Rosella ^a   Racca, Patrizia ^a   Micari, Jasmin ^a   Degiuli, Maurizio ^a   Carletto, Sara ^a,b   Tizzani, Alessandro ^a   Matera, Lina ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Colorectal cancer; Dendritic cells; Myeloid derived suppressor cells; Prostate cancer; Vaccine therapy

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; PHORBOL 13 ACETATE 12 MYRISTATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSOR CELL; MALE; MONOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; T LYMPHOCYTE; TUMOR ABLATION;

COLORECTAL CANCER; DENDRITIC CELLS; MYELOID DERIVED SUPPRESSOR CELLS; PROSTATE CANCER; VACCINE THERAPY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD11B; ANTIGENS, CD14; CANCER VACCINES; COLORECTAL NEOPLASMS; DENDRITIC CELLS; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNOCOMPETENCE; MALE; MIDDLE AGED; MONOCYTES; PROSTATECTOMY; PROSTATIC NEOPLASMS; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84884979960     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12086     Document Type: Article

References (38)

1. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372-383.
2. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J. Immunol. 2011; 186: 1325-1331.
3. Andrews DM, Maraskovsky E, Smyth MJ. Cancer vaccines for established cancer: how to make them better? Immunol. Rev. 2008; 222: 242-255.
4. Kantoff PW, Higano CS, Shore ND etal. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010; 363: 411-422.
5. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumour cells. Annu. Rev. Immunol. 2007; 25: 267-296.
6. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006; 66: 5527-5536.
7. Herr HW. Suppressor cells in immunodepressed bladder and prostate cancer patients. J. Urol. 1980; 123: 635-639.
8. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 2006; 177: 7398-7405.
9. Harris AL, Banham AH, Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol. Immunother. 2007; 56: 81-87.
10. Kiniwa Y, Miyahara Y, Wang HY etal. CD8+Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 2007; 13: 6947-6958.
11. Yokokawa J, Cereda V, Remondo C etal. Enhanced functionality of CD4+CD25highFoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin. Cancer Res. 2008; 14: 1032-1040.
12. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009; 9: 162-174.
13. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 2009; 27: 669-692.
14. Peranzoni E, Zilio S, Marigo I etal. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 2010; 22: 238-244.
15. Schmielau J, Finn OJ. Activated granulocytes and granulocyte derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001; 61: 4756-4760.
16. Rodriguez PC, Ernstoff MS, Hernandez C etal. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009; 69: 1553-1560.
17. Serafini P, Meckel K, Kelso M etal. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 2006; 203: 2691-2702.
18. Hoechst B, Ormandy LA, Ballmaier M etal. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-243.
19. Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol. 1999; 163: 6251-6260.
20. Vuk-Pavlovic S, Bulur PA, Lin Y etal. Immunosuppressive CD14(+)HLA-DR(low/-) monocytes in prostate cancer. Prostate 2010; 70: 443-455.
21. Ugurel S, Uhlig D, Pfohler C, Tilgen W, Schadendorf D, Reinhold U. Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol. Immunother. 2004; 53: 551-559.
22. Filipazzi P, Valenti R, Huber V etal. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 2007; 25: 2546-2553.
23. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-Sign. Cancer Res. 2010; 70: 4335-4345.
24. Brusa D, Carletto S, Cucchiarale G etal. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes. Prostate 2011; 71: 344-352.
25. Camus M, Tosolini M, Mlecnik B etal. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009; 69: 2685-2693.
26. Coppola D, Nebozhyn M, Khalil F etal. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 2011; 179: 37-45.
27. Brusa D, Migliore E, Garetto S, Simone M, Matera L. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells. Prostate 2009; 69: 1343-1345.
28. Bronte V, Kasic T, Gri G etal. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 2005; 201: 1257-1268.
29. Rigamonti N, Capuano G, Ricupito A etal. Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer. Clin. Cancer Res. 2011; 17: 1012-1023.
30. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2002; 2: 151-161.
31. Wilkinson R, Kassianos AJ, Swindle P, Hart DNJ, Radford KJ. Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate 2006; 66: 180-192.
32. Sciarra A, Lichtner M, Autran Gomez AM etal. Characterization of Circulating Blood Dendritic Cell Subsets DC123+ (Lymphoid) andDC11C+ (Myeloid) in Prostate Adenocarcinoma Patients. Prostate 2007; 67: 1-7.
33. Garetto S, Sizzano F, Brusa D, Tizzani A, Malavasi F, Matera L. Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation. Cytotherapy 2009; 11: 1090-1100.
34. Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev. 2006; 25: 323-331.
35. Ostrand-Rosenberg S, Sinh P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009; 182: 4499-50.
36. Gibbons RA, Martinez OM, Lim CR, Horn JK, Garovoy MR. Reduction in HLA-DR, HLA-DQ and HLA-DP expression by Leu-M3+ cells from the peripheral blood of patients with thermal injury. Clin. Exp. Immunol. 1989; 75: 371-375.
37. Zhu B, Bando Y, Xiao S etal. CD11b1Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 2007; 179: 5228-5237.
38. Haile LA, von Wasielewski R, Gamrekelashvili J etal. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008; 135: 871-881.